Mon, Dec 29, 2014, 12:03 PM EST - U.S. Markets close in 3 hrs 57 mins

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Jun 6, 2014 5:39 PM Flag

    This trial completed in the last 3 weeks. If results are positive then

    Then you will see powerful gains in CLDX.

    Celldex and Rockefeller University investigators are collaborating on an effort to develop a vaccine against the human immunodeficiency virus (HIV), the virus known to cause Acquired Immune Deficiency Syndrome (AIDS). The vaccine, called DCVax-001, is an APC-targeted vaccine consisting of a fusion protein of a human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program has been funded through a grant from the Bill & Melinda Gates Foundation. The vaccine is currently being tested in a Phase 1 trial in healthy volunteers at Rockefeller University.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Tibor Keler and those silly investigators at Rockefeller thought they were finished with this study last year when they presented the results.

      •  CD4+ T cell responses were induced in all 3 dose groups. Responses
      are consistently detectable and persisted at 12 months after last
      immunization in all dose groups.

      •  Transient and modest CD8 responses were observed in the mid and
      high dose groups

    • I believe that when a trial officially completes and when it reports are two very different things. Sorry I could state this in a highly inflammatory and therefore entertaining way. Not my style.

    • DEC-205 has already shown good results. You can see my post earlier today.

      Sentiment: Strong Buy

    • Trust me, it just ended, regardless what the original completion date was.

      DCVax Plus Poly ICLC in Healthy Volunteers
      This study has been completed.
      Rockefeller University
      Information provided by (Responsible Party):
      Rockefeller UniversityClinicalTrials.gov Identifier:
      NCT01127464
      First received: May 19, 2010
      Last updated: May 7, 2014
      Last verified: May 2014
      History of Changes Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record Purpose
      DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection. The vaccine is composed of a fusion protein containing a human monoclonal antibody specific for the dendritic cell receptor, DEC-205 (CD205), and the HIV gag p24 protein. The vaccine is designed to target HIV antigens directly to endocytic pathways in dendritic cells (DCs) that allow for efficient processing and presentation of multiple HIV peptides on both MHC class I and II products, which will induce HIV-specific CD8+ and CD4+ T cells. This vaccine candidate must be combined with appropriate immunostimulants (adjuvants) to induce immunity to the antigen. In the proposed clinical trial we will use poly ICLC (Hiltonol) from Oncovir, Inc as the adjuvant.

      Sentiment: Strong Buy

    • With all due respect and no sarcasm, what the F are you talking about, as the poster below pointed out trail completed 2 years ago, without a peep

    • Study Completion Date: November 2012

      https://clinicaltrials.gov/ct2/show/results/NCT01127464

 
CLDX
18.21-0.03(-0.16%)12:03 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.